Shandong Boan Biotechnology Co., Ltd. (UJ9.F)

1.1300 -0.0100 (-0.88%) At close: 09:59AM CEST

Shandong Boan Biotechnology Co., Ltd.

No. 39 Keji Avenue
High-Tech Industrial Development Zone
Yantai
China
86 53 5437 9111
https://www.boan-bio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Hua Jiang	Executive Chairlady & CEO	392.02k	N/A	1978
Dr. Changlin Dou	COO, President of R&D and Executive Director	602.9k	N/A	1963
Mr. Shenghan Wang	Chief Financial Officer	N/A	N/A	1979
Mr. Jun Lu	Senior VP and Head of Biotechnology Engineering Center & Quality Department	N/A	N/A	1966
Mr. Deyong Song	Head of Biologics Discovery Department	N/A	N/A	1982
Chunna You	Senior Vice President of R&D Center	N/A	N/A	N/A
Zhou Ming	Chief Medical Officer	N/A	N/A	N/A
Ms. Siu Kuen Lai FCIS, FCS	Company Secretary	N/A	N/A	1976

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in the People's Republic of China and internationally. Its commercialized products include Boyounuo (BA1101) bevacizumab injection for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), advanced recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer; and Boyoubei BA6101, a human immunoglobulin G2 monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The company develops BA1102 denosumab injection to treat patients with skeletal-related events caused by multiple myeloma and bone metastases from solid tumors, as well as GCTB; and LY-CovMab to treat COVID-19. It also develops BA9101 aflibercept intraocular injection to treat patients with wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, and retinopathy of prematurity; BA1104 to treat patients with melanoma, NSCLC, malignant pleural mesothelioma, RCC, classical hodgkin lymphoma, SCCHN, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal and gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; and BA5101 to treat patients with type 2 diabetes. In addition, the company develops BA1105, a recombinant anti-Claudin 18.2 fully human IgG1 monoclonal antibody; BA1201, an anti-PD-L1/TGF-ß bifunctional fusion protein intended for the treatment of SCLC, NSCLC, cervical cancer, urothelial carcinoma, and advanced gastrointestinal tumors; BA1106, a CD25 fully human monoclonal antibody; BA1202, a bispecific antibody; and BA1301, an anti-Claudin 18.2 antibody-drug conjugate; BA2101, an IL4R long-acting molecular antibody. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is subsidiary of Shandong Luye Pharmaceutical Co., Ltd.

Corporate governance

Shandong Boan Biotechnology Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.